CRP and Inflammation Statistics 2026

CRP Reference Ranges

• High-sensitivity CRP (hs-CRP) values below 1.0 mg/L, 1.0 to 3.0 mg/L, and above 3.0 mg/L are interpreted as lower, average, and higher relative cardiovascular risk, respectively, in the framework endorsed by the American Heart Association and the U.S. Centers for Disease Control and Prevention. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696
• The prognostic information that hs-CRP adds about cardiovascular risk is comparable in strength to that provided by blood pressure or cholesterol. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696
• A single CRP measurement above 10 mg/L generally reflects an acute event such as infection or injury rather than the low-grade chronic inflammation that hs-CRP testing is designed to detect, according to the AHA and CDC scientific framework for CRP interpretation. Source: American Heart Association and CDC framework, summarized in Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696
• In current U.S. guidelines, hs-CRP carries a Class IIb recommendation and is considered most useful in primary prevention when the decision to start statin therapy is otherwise uncertain. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696

Tier definitions per Ridker PM, J Am Coll Cardiol 2016 (PubMed 26868696), summarizing the AHA and CDC statement on markers of inflammation.

CRP and Cardiovascular Risk

• In an individual-participant meta-analysis of 160,309 people without prior vascular disease, each threefold higher CRP concentration was associated with a 1.63-fold higher risk of coronary heart disease when adjusted for age and sex. Source: Emerging Risk Factors Collaboration, Lancet 2009. PubMed 20031199
• In the same meta-analysis of more than 160,000 people, each threefold higher CRP concentration was associated with a 1.44-fold higher risk of ischemic stroke before adjustment for conventional risk factors. Source: Emerging Risk Factors Collaboration, Lancet 2009. PubMed 20031199
• After adjustment for conventional risk factors, the association between a threefold higher CRP level and coronary heart disease fell to a 1.37-fold higher risk, showing that part of CRP's predictive value overlaps with established risk factors. Source: Emerging Risk Factors Collaboration, Lancet 2009. PubMed 20031199
• In a study of 27,939 apparently healthy American women followed for eight years, CRP was a stronger predictor of first cardiovascular events than LDL cholesterol. Source: Ridker PM et al, N Engl J Med 2002. PubMed 12432042
• Among those same women, the relative risk of a first cardiovascular event rose to 2.3 times higher in the highest CRP quintile compared with the lowest, after adjustment for age, smoking, diabetes, blood pressure, and hormone therapy. Source: Ridker PM et al, N Engl J Med 2002. PubMed 12432042
• In the JUPITER trial of 17,802 apparently healthy adults with LDL cholesterol below 130 mg/dL and hs-CRP of 2.0 mg/L or higher, rosuvastatin reduced the combined rate of heart attack, stroke, and cardiovascular death by 44 percent (hazard ratio 0.56). Source: Ridker PM et al, N Engl J Med 2008 (JUPITER). PubMed 18997196
• In the JUPITER trial, statin therapy lowered hs-CRP levels by 37 percent alongside a 50 percent reduction in LDL cholesterol. Source: Ridker PM et al, N Engl J Med 2008 (JUPITER). PubMed 18997196
• In the CANTOS trial of 10,061 patients who had a prior heart attack and an hs-CRP of 2 mg/L or higher, the interleukin-1 beta inhibitor canakinumab reduced cardiovascular events without lowering cholesterol, the first trial to show that reducing inflammation alone can lower cardiovascular risk. Source: Ridker PM et al, N Engl J Med 2017 (CANTOS). PubMed 28845751
• In CANTOS, the 150 mg dose of canakinumab lowered hs-CRP by about 37 percentage points more than placebo at 48 months while leaving lipid levels unchanged. Source: Ridker PM et al, N Engl J Med 2017 (CANTOS). PubMed 28845751
• Higher CRP concentration is associated in large prospective data with increased risk not only of coronary heart disease and ischemic stroke but also of vascular mortality and non-vascular mortality. Source: Emerging Risk Factors Collaboration, Lancet 2009. PubMed 20031199

CRP and Lifestyle Factors

• In a study of 5,503 healthy adults, current smokers were 55 percent more likely to have an elevated hs-CRP above 3 mg/L than non-smokers. Source: Jamal O et al, Diabetol Metab Syndr 2014. PubMed 25960769
• Among adults with metabolic syndrome in the same study, smokers were more than twice as likely to have elevated hs-CRP compared with non-smokers, showing that smoking and metabolic syndrome add together to raise inflammation. Source: Jamal O et al, Diabetol Metab Syndr 2014. PubMed 25960769
• In the PREDIMED trial, a Mediterranean diet supplemented with virgin olive oil reduced CRP by 0.54 mg/L over three months compared with a low-fat diet. Source: Estruch R et al, Ann Intern Med 2006 (PREDIMED). PubMed 16818923
• In a meta-analysis of 72 studies covering more than 50,000 people, sleep disturbance was associated with higher circulating CRP levels. Source: Irwin MR et al, Biol Psychiatry 2015. PubMed 26140821
• The same sleep meta-analysis found that both short habitual sleep and long sleep duration were associated with higher CRP, indicating a U-shaped relationship between sleep and inflammation. Source: Irwin MR et al, Biol Psychiatry 2015. PubMed 26140821
• In the STEP-HFpEF trial, substantial weight loss produced by semaglutide lowered CRP by 43.5 percent over 52 weeks, compared with a 7.3 percent reduction on placebo. Source: Kosiborod MN et al, N Engl J Med 2023 (STEP-HFpEF). PubMed 37622681
• Diet, exercise, and smoking cessation are the recommended first steps for lowering CRP in people with a proinflammatory profile, before any consideration of medication. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696

Inflammation Prevalence

• In a cohort of 5,503 healthy non-diabetic adults, 19 percent had an hs-CRP above 3 mg/L, the threshold for the higher relative cardiovascular risk tier. Source: Jamal O et al, Diabetol Metab Syndr 2014. PubMed 25960769
• In a prospective cohort of 40,813 non-diabetic adults followed for a median of about eight years, higher cumulative hs-CRP was independently associated with a greater risk of developing type 2 diabetes. Source: Wu D et al, J Transl Med 2024. PubMed 38281997
• In a meta-analysis of 11 studies including 1,618 people, CRP levels were significantly elevated in people with bipolar disorder compared with control subjects, reflecting the link between mood conditions and low-grade inflammation. Source: Dargel AA et al, J Clin Psychiatry 2015. PubMed 25742201
• Higher CRP concentration is associated in large prospective data with increased death from several cancers and from lung disease, in addition to vascular causes. Source: Emerging Risk Factors Collaboration, Lancet 2009. PubMed 20031199

CRP Testing

• The high-sensitivity CRP assay is the version of the test used to measure low-grade chronic inflammation, because standard CRP assays are calibrated for the much higher levels seen in acute infection. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696
• Because a single CRP reading can be temporarily raised by a cold, injury, or recent intense exercise, repeat testing and trends over time give a more reliable picture than any one result, consistent with how the AHA and CDC framework treats CRP as a risk marker rather than a one-time diagnosis. Source: Ridker PM, J Am Coll Cardiol 2016. PubMed 26868696
• Genetic factors are estimated to explain roughly 20 to 40 percent of the variation in CRP levels between people, which means most of a person's CRP is shaped by modifiable factors such as weight, diet, activity, and smoking. Source: Ridker PM and Silvertown JD, J Periodontol 2008. PubMed 18673009
• Risk models that add hs-CRP to standard risk factors, such as the Reynolds Risk Score, have been shown to improve classification for people rated at intermediate risk by older algorithms like the Framingham Risk Score. Source: Ridker PM and Silvertown JD, J Periodontol 2008. PubMed 18673009

Costs are general ranges for orientation only and vary widely by region, provider, and insurance. They are not quoted from a single study and should be confirmed with the specific lab or provider.